ライフサイエンスコーパス: tolerogenic

1 al DC activation states, from immunogenic to tolerogenic.

2 This presumed tolerogenic action turned out to be a sensitization proc

3 Whereas intact VCAN exerts tolerogenic activities through Toll-like receptor 2 (TLR

4 C1q, and semaphorins, which promote myeloid tolerogenic activity by driving PD-L1 overexpression in

5 om CCR2 mice failed to be mobilized and lost tolerogenic activity in vivo, but sustained suppressive

6 tumor growth, affected the accumulation and tolerogenic activity of MDSCs in tumors, and inhibited t

7 Supporting its tolerogenic activity, Gal1 expression decreased with age

8 ritic cell (DC) function from immunogenic to tolerogenic activity.

9 lated the in vivo switch from immunogenic to tolerogenic activity.

10 he intake of probiotic Lactococcus lactis as tolerogenic adjuvant (combined therapy).

11 tiation and is able to promote a distinctive tolerogenic and anti-inflammatory profile on monocyte-de

12 his shift in metabolism, which regulates the tolerogenic and immunogenic responses of DCs.

13 mmune response but also need to overcome the tolerogenic and immunosuppressive microenvironments that

14 ur findings reveal that the conflict between tolerogenic and inflammatory intestinal responses is in

15 t is unclear how they simultaneously support tolerogenic and inflammatory reactions.

16 Interestingly, tolerogenic and mature DCs manifested substantially diff

17 At the level of glycolysis, tolerogenic and mature DCs showed similar glycolytic rat

18 sets differing susceptibility to the in vivo tolerogenic anti-CD3-mediated modulation.

19 The tolerogenic anti-CD3epsilon monoclonal Abs (anti-CD3) ar

20 rgeting the CD45 tyrosine phosphatase with a tolerogenic anti-CD45RB mAb acutely increases Treg numbe

21 ons skewing their polarization toward a more tolerogenic anti-inflammatory phenotype.

22 KIM-1-mediated phagocytosis leads to pro-tolerogenic antigen presentation, which suppresses CD4 T

23 egs from a variety of human monocyte-derived tolerogenic antigen-presenting cells in current developm

24 toli cells, can function as non-professional tolerogenic antigen-presenting cells, and sustain the bl

25 uires reactivation following exposure to the tolerogenic antigen.

26 ation, we investigated whether enrichment of tolerogenic APCs (tolAPCs) in donor corneas can enhance

27 the gut microbiota, as well as induction of tolerogenic APCs, which led to reduced activation of dia

28 Langerhans cells (LC) can prime tolerogenic as well as immunogenic responses in skin, bu

29 ve HDAC6 inhibitor disrupts this STAT3/IL-10 tolerogenic axis points to HDAC6 as a novel molecular ta

30 o overcome these limitations, we generated a tolerogenic bacterial delivery technology based on live

31 athways to maintain a salubrious immunogenic/tolerogenic balance.

32 a future tool for the targeted induction of tolerogenic Bregs.TRIAL REGISTRATIONEudraCT number: 2014

33 itions and may contribute to the homeostatic tolerogenic capacity of DCs.

34 In this study, we analyzed the tolerogenic capacity of IL-10-modulated DC (IL-10DC) sub

35 e immunomodulatory responses, frequencies of tolerogenic CD103(+) and plasmacytoid dendritic cells we

36 ells and the accumulation of a population of tolerogenic CD103(+) dendritic cells (DCs) in the spleen

37 proportions of Foxp3(+) regulatory T cells, tolerogenic CD103(+) dendritic cells, and less Il10 gene

38 nt of oral tolerance to ovalbumin, levels of tolerogenic CD103(+) dendritic cells, and regulatory T (

39 ic cells (DCs), whereas UV-Ct accumulated in tolerogenic CD11b(-)CD103(+) DCs.

40 Here we show that the number of peripheral tolerogenic CD1c(+) dendritic cells (DCs) and the levels

41 g RNA in MSCs abolishes the up-regulation of tolerogenic CD1c(+)DCs in lupus patients treated with MS

42 e proliferation and inhibit the apoptosis of tolerogenic CD1c(+)DCs.

43 DCIR2(+) DCs but not DEC-205(+) DCs elicited tolerogenic CD4(+) T-cell responses in NOD mice.

44 associated with inadequate reconstitution of tolerogenic CD4(+)CD25(+)FOXP3(+) regulatory T cells (Tr

45 Tolerogenic CD8(+) DCs induced the development of tolero

46 ell response, as evidenced by a reduction of tolerogenic CD8+CD122+ T cells and an increase of cytoto

47 sonins in determining the immunogenic versus tolerogenic characteristics of self antigens.

48 lacking Gal-1 interrupted the Gal-1-mediated tolerogenic circuit and reinforced T cell-dependent anti

49 We identify a novel tolerogenic circuit encompassing suppressive CD1c(+) DCs

50 isplaying both Ag and CD22 ligands induces a tolerogenic circuit resulting in apoptosis of the Ag-rea

51 immune components, leading to disruption of tolerogenic circuits and development of autoimmune disor

52 may influence T. cruzi infection by fueling tolerogenic circuits that hinder anti-parasite immunity.

53 a failure in the activation of Gal-1-driven tolerogenic circuits, otherwise orchestrated by WT dendr

54 Here we show that loss of MZMs impairs the tolerogenic clearance of apoptotic cells and alters the

55 her evaluation to determine translation to a tolerogenic clinical outcome.

56 n, a brief overview and update on cell-based tolerogenic clinical trials is provided.

57 entional CD4 T cells, TCR-stimulated under a tolerogenic conditioned medium, could be ex vivo reprogr

58 oislets were transplanted after optimized CT tolerogenic conditioning (1 x 25 mug [CT25]).

59 developmentally linked and GITR can subvert tolerogenic conditions to boost Th9 immunity.

60 e sensing of myeloma tumors and modulate the tolerogenic consequences of intact VCAN accumulation.

61 ining peripheral Ags to LECs, which maintain tolerogenic cross-presentation of such Ags.

62 A more aggressive approach involving tolerogenic cytokine administration and/or lymphocyte de

63 cell proliferation but higher levels of the tolerogenic cytokine IL-10 and the Th1 cytokine IFN-gamm

64 The tolerogenic cytokine IL9 promotes T regulatory cell func

65 suppressive Treg-specific cytokine and as a tolerogenic cytokine that efficiently inhibits alloreact

66 In contrast to the production of tolerogenic cytokines (IL-4 and IL-10) in the recipients

67 e animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines produ

68 ) regulatory T cells (Treg cells) expressing tolerogenic cytokines.

69 biomarkers of gut barrier integrity, and of tolerogenic cytokines.

70 L-23), with no increase in the expression of tolerogenic DC genes.

71 This tolerogenic DC phenotype and function was marked by a ne

72 ore, the scientific rationale for the use of tolerogenic DC therapy in the fields of allergies, autoi

73 AhR pathway in maintaining IDO expression in tolerogenic DC.

74 rapy showed an increase in induced Tregs and tolerogenic DCs accompanied by the downregulation of the

75 ective immunoregulatory circuit encompassing tolerogenic DCs and forkhead box P3(+) Treg cells that c

76 hanisms and functions of natural and induced tolerogenic DCs and offer further insight into how their

77 Inhibition of FAO prevented the function of tolerogenic DCs and partially restored T cell stimulator

78 toimmunity via the induction of skin-derived tolerogenic DCs and Tregs.

79 ized the transcriptional networks induced in tolerogenic DCs by Act-A-iTreg cells.

80 Functionally, tolerogenic DCs demonstrated the highest mitochondrial o

81 unced proinflammatory program of mature DCs, tolerogenic DCs displayed a markedly augmented catabolic

82 firm the importance of BLIMP1 in maintaining tolerogenic DCs in both mice and humans.

83 he cross-talk between gammadelta T cells and tolerogenic DCs in the gut.

84 Overall, tolerogenic DCs show metabolic signatures of increased o

85 These "induced tolerogenic DCs" help to moderate immune responses such

86 isms constitutively present in such "natural tolerogenic DCs" help to promote tolerance to peripheral

87 omplexes were significantly more abundant in tolerogenic DCs.

88 and FAO activity was significantly higher in tolerogenic DCs.

89 capacity and reserve were more pronounced in tolerogenic DCs.

90 neutrophils, resulting in an upregulation of tolerogenic DCs.

91 rough which ATRA promotes the development of tolerogenic DCs.

92 inflammation in lupus through up-regulating tolerogenic DCs.

93 er corroborates the potential of prospective tolerogenic DEC205(+) DC vaccination to interfere with a

94 nistration of autologous (recipient-derived) tolerogenic dendritic cells (ATDCs) is under clinical ev

95 ation with TLR2 ligand from S. aureus induce tolerogenic dendritic cells (DCs) characterized by the p

96 Tolerogenic dendritic cells (DCs) have emerged as releva

97 ulatory T (Treg) cells through generation of tolerogenic dendritic cells (DCs) in an allergic airways

98 ), which may contribute to the generation of tolerogenic dendritic cells (DCs) in the liver.

99 Treg-inducing tolerogenic dendritic cells (DCs) were further necessary

100 During homeostasis, interactions between tolerogenic dendritic cells (DCs), self-reactive T cells

101 g has recently been tied to the emergence of tolerogenic dendritic cells (DCs).

102 Tolerogenic dendritic cells (TolDCs) are one such therap

103 Tolerogenic dendritic cells (tolDCs) may offer an intere

104 ng, there were statistically increased blood tolerogenic dendritic cells and cell phenotypes correlat

105 dendrocyte glycoprotein (MOG)(35-55) induced tolerogenic dendritic cells and suppressed the developme

106 a following immunization, reduced numbers of tolerogenic dendritic cells and Treg cells in the intest

107 CD43 between immunogenic dendritic cells and tolerogenic dendritic cells appears to contribute to the

108 gs), alternatively activated macrophages and tolerogenic dendritic cells are dominant in the TME.

109 Neither regulatory B cells nor tolerogenic dendritic cells contributed to immunosuppres

110 (+) T cells (CD4(+) T cells coincubated with tolerogenic dendritic cells pulsed with the main peanut

111 Tolerogenic dendritic cells were differentiated in the p

112 roach combining administration of autologous tolerogenic dendritic cells with short-term treatment wi

113 een Ig-like transcript 3 (ILT3), a marker of tolerogenic dendritic cells, also known as LILRB4/LIR5/C

114 ns that is characterized by the induction of tolerogenic dendritic cells, an increase in regulatory T

115 regulatory B cells, regulatory macrophages, tolerogenic dendritic cells, and myeloid-derived suppres

116 aning, there were statistically higher blood tolerogenic dendritic cells, regulatory B cells, and cel

117 e phenotype and function of 3 types of RMCs, tolerogenic dendritic cells, suppressor macrophages, and

118 cells, but it has no effect on migration of tolerogenic dendritic cells.

119 peated antigen exposure or in vitro by using tolerogenic dendritic cells.

120 ng tissue emigration of immunogenic, but not tolerogenic, dendritic cells, providing an additional me

121 We hypothesized that the tolerogenic difference of the kidneys might be due to di

122 ctive is to develop an adoptive therapy with tolerogenic donor-specific type 1 T regulatory cells for

123 We have previously demonstrated that the tolerogenic effect mediated by CD8(+)CD45RC(low) regulat

124 t insight into the mechanisms underlying the tolerogenic effects of B10 cells in EAMG.

125 r, the results provide new insights into the tolerogenic effects of costimulatory blockade and identi

126 The tolerogenic effects of NK1.1(+) cells are mediated throu

127 monstrate that PD-L1(+) T cells have diverse tolerogenic effects on tumor immunity.

128 reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and

129 The liver is a tolerogenic environment exploited by persistent infectio

130 The unusual immune repertoire and tolerogenic environment of the liver may explain why thi

131 The liver maintains a tolerogenic environment to avoid unwarranted activation

132 sponse to intestinal antigens by promoting a tolerogenic environment via manipulation of DC populatio

133 and generates a long-lived, antigen-specific tolerogenic environment.

134 cytokines (IL-10, TGF-beta1, and IL-2) and a tolerogenic enzyme (IDO) in bone marrow-derived dendriti

135 Incorporation of gene therapy to drive tolerogenic expression of antigens is a promising strate

136 uire TMEM176B to cross-present antigens in a tolerogenic fashion.

137 The dual tolerogenic features that Sia-antigen imposed on DCs are

138 ghest degree of phosphorylation was the most tolerogenic following retreatment with LOS or whole bact

139 d proinflammatory CD3+CD4+IL-17+ and reduced tolerogenic Foxp3+ Treg lymphocytes (Tregs).

140 The tolerogenic function of intestinal DCs was tested by ado

141 a/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs)

142 OS(-/-) mice exhibited near complete loss of tolerogenic function, despite sustained Arg-1 activity.

143 d neurodegenerative microglia had lost their tolerogenic function.

144 at IFN-gamma signaling in DCs mediates their tolerogenic function.

145 stimulated DCs, favoring the development of tolerogenic functions and finally resulting in T-cell to

146 tiviral immunity, exhibit proinflammatory or tolerogenic functions depending on the context, yet thei

147 e responses, but certain signals also induce tolerogenic functions in DCs.

148 We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer

149 te DC responses and endow them with enhanced tolerogenic functions.

150 of oral tolerance to DNFB through licensing tolerogenic gut DCs.

151 nhibitory cell surface receptor expressed by tolerogenic human dendritic cells.

152 sms including immune editing, recruitment of tolerogenic immune cells, and secretion of immunosuppres

153 e located in the healthy epidermis and exert tolerogenic immune functions.

154 The liver provides a tolerogenic immune niche exploited by several highly pre

155 ibit long-term survival in vivo and prompt a tolerogenic immune response characterized by elevated IL

156 her treatment with oral insulin can induce a tolerogenic immune response in children genetically susc

157 ment with highly nitrated proteins induces a tolerogenic immune response in the food allergy model an

158 of allergic diseases entails an ineffective tolerogenic immune response to allergens.

159 nfluence the development of inflammatory and tolerogenic immune responses.

160 igen-specific regulatory T cells (Tregs) and tolerogenic immunity.

161 ing either protein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durabl

162 In conclusion, GMCSF-NAg was tolerogenic in CFA-primed proinflammatory environments b

163 rent pathways of activation, immunogenic and tolerogenic, induce different changes in the lipid compo

164 homa cells by anti-KIR antibodies prevents a tolerogenic interaction and augments NK-cell spontaneous

165 f fetal tolerance, it is not known how these tolerogenic leukocytes are induced.

166 n 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune s

167 hrough T-cell inhibition, and programming of tolerogenic macrophages.

168 rface MHC class II (MHCII) and promoting the tolerogenic markers, programmed death-ligand (PD-L)1, PD

169 s article, we report that proteolysis of the tolerogenic matrix proteoglycan versican (VCAN) strongly

170 H)2D3], is able to promote the generation of tolerogenic mature dendritic cells (mDCs) with an impair

171 s, any cell could, in principle, invoke this tolerogenic mechanism for cell surface Ags.

172 We speculate that this tolerogenic mechanism is a contributing factor in DST an

173 Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent

174 a dysfunctional immune synapse as a pivotal tolerogenic mechanism.

175 ecently developed therapeutics that overcome tolerogenic mechanisms activate tumour-directed CTLs and

176 Treatment with recombinant Gal1 restored tolerogenic mechanisms and reduced salivary gland inflam

177 The underlying tolerogenic mechanisms are incompletely understood.

178 because of the inherent immune privilege and tolerogenic mechanisms associated with the anterior segm

179 We hypothesized that similar tolerogenic mechanisms prevent their rejection.

180 The effect of HM butyrate on tolerogenic mechanisms was assessed in in vivo and in vi

181 of immune responses, enhanced regulatory and tolerogenic mechanisms, and immune system immaturity, ma

182 Among the tolerogenic mechanisms, the expression of the enzyme IDO

183 regulatory T cells (Tregs) in the underlying tolerogenic mechanisms.

184 promote tolerance but their contributions to tolerogenic memory are unclear.

185 upon allergen re-challenge or contribute to tolerogenic memory.

186 arcinogenic inflammation and contribute to a tolerogenic microenvironment in tumors.

187 iver is an immunoregulatory organ in which a tolerogenic microenvironment mitigates the relative "str

188 Airway epithelial cells mount a tolerogenic microenvironment that reduces the proinflamm

189 Islet CCL22 expression thus produces a tolerogenic milieu through the interplay of Tregs, invar

190 rexpression alone is sufficient to promote a tolerogenic mode of function in DCs.

191 ation, and to generate immune responses in a tolerogenic model of chronic infection, indicates that V

192 to recombinant hTSHR A-subunit protein and a tolerogenic molecule (ligand for the endogenous aryl-hyd

193 In conclusion, despite the inclusion of a tolerogenic molecule, injected nanoparticles coated with

194 bitory capacities through the involvement of tolerogenic molecules (HLA-G, TGF-beta, and IL-10) were

195 analyzed the expression of costimulatory and tolerogenic molecules by pulmonary CD1c(+) DCs from pati

196 40 signaling, leading to the upregulation of tolerogenic molecules, such as IL-10 and PD-L1.

197 ith oncogenic KRAS-induced inflammation, the tolerogenic myeloid cell infiltrate has emerged as a cri

198 r (AHR) to drive the generation of Tregs and tolerogenic myeloid cells and PD-1 up-regulation in CD8(

199 Tolerogenic nanoparticle therapy represents a potential

200 Adjunct therapy with tolerogenic nanoparticles represents a novel and broadly

201 Treatment with tolerogenic nanoparticles results in the inhibition of C

202 Intravenous co-administration of tolerogenic nanoparticles with pegylated uricase inhibit

203 it is in humans due at least in part to the tolerogenic nature of the liver.

204 ogenic CD8(+) DCs induced the development of tolerogenic NKT cells with a marked T helper 2 cell bias

205 the immune environment, pDCs exhibit either tolerogenic or immunogenic properties.

206 Dendritic cells (DCs) promote either tolerogenic or immunogenic T cell responses, the latter

207 Thus, DCs modulate their ability to prime tolerogenic or immunogenic T cells by expressing a core

208 The mucosal immune system is a unique tolerogenic organ that provides a physiological approach

209 Thus, using APL as a model, we uncover a tolerogenic pathway that may represent a relevant immuno

210 the complex repertoire of cells that promote tolerogenic pathways in the periphery, 2 key classes inc

211 protein by ~90%, disrupting immunogenic and tolerogenic pathways to different degrees.

212 downregulates TH2 immune responses, induces tolerogenic pathways, and increases regulatory T cells.

213 zation to food fails to stimulate protective tolerogenic pathways, leading to the development of the

214 ently exceeded, interventions with different tolerogenic PEG-liposomes.

215 ffectiveness of prophylaxis with free PEG or tolerogenic PEGylated liposomes as a strategy to reduce

216 (transforming growth factor)-beta-dependent tolerogenic phenotype and promote the expansion of regul

217 marrow-derived DCs to Zn in vitro induced a tolerogenic phenotype by diminishing surface MHC class I

218 ation and differentiation of DCs by inducing tolerogenic phenotype by modulating the expression of PD

219 host response switch, since RANKL imprint a tolerogenic phenotype in DCs, described to be involved i

220 ight into the mechanisms of the TLR4-induced tolerogenic phenotype in human DCs, which can help the b

221 The mechanisms by which Zn regulates the tolerogenic phenotype of DCs remain largely unknown.

222 ophages and dendritic cells (DCs) promotes a tolerogenic phenotype reversed by PAFR-antagonists treat

223 s process was dependent on IFN-gamma and the tolerogenic phenotype was conferred by IDO.

224 DC-RAs displayed a mature yet tolerogenic phenotype, expressing IL-10, TGF-beta, IL-27

225 um from women with endometriosis exhibited a tolerogenic phenotype, including increased IL-10 product

226 of pathogenic effector T cells toward a more tolerogenic phenotype.

227 neously, KCs lose signature markers of their tolerogenic phenotype.

228 ion in IFN-gamma-treated DCs, resulting in a tolerogenic phenotype.

229 regulatory EVs, revealing the possible self-tolerogenic potential of autologous erythrocytes.

230 Thus, Zn shapes the tolerogenic potential of DCs in vitro and in vivo and pr

231 The self-tolerogenic potential of EVs was determined in a newly d

232 biting the development of MHCII(low) DC with tolerogenic potential.

233 induce autoimmune diabetes, indicating their tolerogenic potential.

234 However, tolerogenic processes remain poorly understood, and stra

235 ducing inflammatory responses and regulating tolerogenic processes.

236 capacity of 1,25(OH)2D3 to imprint a similar tolerogenic profile in cells derived from diabetes-prone

237 1,25(OH)2D3 is able to imprint a phenotypic tolerogenic profile on DCs derived from both mouse strai

238 However, the drivers of this tolerogenic program are incompletely defined.

239 antigens instruct DCs in an antigen-specific tolerogenic programming, enhancing Treg cells and reduci

240 l in potentiating the generation of DCs with tolerogenic properties by Act-A-iTreg cells.

241 e IL-33/ST2 pathway, aiming to exploit their tolerogenic properties for cell therapy.

242 igate the potential influence of alum in the tolerogenic properties imprinted by PM at the molecular

243 boptimal glycemic control and assessed their tolerogenic properties in correlation with metabolic sta

244 r novel mechanisms by which alum impairs the tolerogenic properties induced by PM, which might well c

245 Our findings indicate that the tolerogenic properties of allogeneic apoptotic splenocyt

246 COPD by examining the immunostimulatory and tolerogenic properties of pulmonary CD1c(+) DCs.

247 the resolution of a severe infection acquire tolerogenic properties that contribute to persistent imm

248 Because of their tolerogenic properties, regulatory T cells (Tregs) play

249 ions, some DCs are characterized by inherent tolerogenic properties.

250 val after liver replacement because of these tolerogenic properties.

251 jects to lungs of patients with COPD confers tolerogenic properties.

252 Mer acted as a tolerogenic receptor in resting macrophages and during i

253 s critical determinants for the induction of tolerogenic regulatory CD4(+) T-cell differentiation.

254 pe-1 and type-17 paradigms at the expense of tolerogenic regulatory T-cell patterns.

255 key role for GCN2 signals in regulating the tolerogenic response to apoptotic cells and limiting aut

256 -draining gLNs preferentially giving rise to tolerogenic responses and the distal gLNs to pro-inflamm

257 ogenic adipocytes, which indirectly regulate tolerogenic responses in intestinal epithelial cells.

258 s in the skin and lungs but also homeostatic tolerogenic responses in the thymus and gut.

259 Failure to induce tolerogenic responses to allergens incites allergic infl

260 cation of IL-1beta or alpha-toxin diminishes tolerogenic responses to S. epidermidis.

261 onists, and apoptotic cells can also promote tolerogenic responses via STING by activating immunoregu

262 Tolerogenic responses were dependent on induction of vit

263 teraction of innate and adaptive immunity in tolerogenic responses.

264 iphery, dendritic cells (DCs) play a crucial tolerogenic role, extending the maintenance of immune ho

265 bundant mucosal Th17 cells, a deficit in the tolerogenic RORgammat(+) regulatory T (Treg) cell subset

266 ligands on the Ag-bearing cells, producing a tolerogenic signal involving Lyn and the proapoptotic fa

267 comes are due to a biochemical uncoupling of tolerogenic signaling, or simply a quantitative reductio

268 APCs will be presented without PD-L1 induced tolerogenic signalling, perhaps initiating disease.

269 focused on the uptake of ACs by phagocytes, tolerogenic signals exposed by the ACs are much less wel

270 the surface of ACs to function as redundant tolerogenic signals in vitro and in vivo.

271 sting that a combination of inflammatory and tolerogenic signals promote c-Maf expression.

272 et resulted in increased numbers of CD103(+) tolerogenic splenic DCs, with a concomitant increase in

273 Unraveling how the reactive versus tolerogenic state is controlled might point toward novel

274 cute-phase conditions, induces a semimature, tolerogenic state on human monocyte-derived dendritic ce

275 hCG also retained dendritic cells in a tolerogenic state that is likely to contribute to both T

276 how STING-dependent DNA sensing can enhance tolerogenic states in tumors characterized by low antige

277 ng the plasticity of NK cells in response to tolerogenic stimuli.

278 physical disruption of cell-cell contacts a tolerogenic stimulus.

279 aused irreversible damage to a population of tolerogenic stromal cells that display peripheral tissue

280 fer of ex vivo-generated immune-promoting or tolerogenic T cells to either enhance immunity or promot

281 c antigen-presenting cells, which results in tolerogenic T-cell education, could be exploited to indu

282 jective measurements of the effectiveness of tolerogenic therapies, and to allow intelligent immunosu

283 Development of tolerogenic therapies, other than standard immune tolera

284 g of Treg suspensions generated for adoptive tolerogenic therapies.

285 l stages, offers a window of opportunity for tolerogenic therapy.

286 certain conditions, LSECs can switch from a tolerogenic to an immunogenic state and promote the deve

287 ed Tregs are a promising approach for future tolerogenic treatment of hemophilia A patients with inhi

288 pment of hESC-derived therapy, combined with tolerogenic treatments, as a sustainable alternative str

289 t mediates tissue damage and by promotion of tolerogenic Treg cells.

290 (Treg) cell commitment, resulting in a more tolerogenic Treg to conventional T cell ratio and protec

291 ce receptors, transcription factors, and the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-

292 Cs presenting the gastric autoantigen remain tolerogenic under such conditions, demonstrating the rob

293 Tolerogenic vaccination required all three components, I

294 This study introduces a flexible format for tolerogenic vaccination that incorporates IFN-beta and n

295 d in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mi

296 evious JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mi

297 Tolerance induction was specific for the tolerogenic vaccine Ag PLP178-191 or myelin oligodendroc

298 An important question was whether GMCSF-NAg tolerogenic vaccines retained inhibitory activity within

299 Since the liver is considered to be tolerogenic, we tested the hypothesis that the renal tra

300 ia gammadelta T cells that, in turn, induces tolerogenic XCR1(+) DC migration to the mesenteric lymph